CD44与消化系统肿瘤的关系及靶向治疗研究进展

消化系统恶性肿瘤发病率和死亡率较高,一直以来影响着人类健康,更有效的诊治策略可提升患者预后。近年来,肿瘤干细胞(CSCs)被认为是肿瘤发生发展的内在因素,是肿瘤复发、转移及放化疗抵抗的重要原因。CD44是一种可与多种配体结合的跨膜单链糖蛋白,已被证实是多种恶性肿瘤的CSCs标志物。经选择性剪切,CD44可产生标准型(CD44s)和变异型(CD44v)等多种亚型。CD44及其亚型可用于肿瘤的诊断、治疗及预后,在消化系统恶性肿瘤发生发展中的作用也被广泛研究。现就CD44及其亚型与消化系统肿瘤的关系及靶向治疗相关研究进展进行综述,以期为临床消化系统疾病的诊治提供参考。

Research progress on CD44 in digestive system tumors and targeted therapy

With high incidence and mortality,digestive system malignant tumors affect human health.More effective diagnosis and treatment strategies can improve the prognosis of patients.In recent years,cancer stem cells(CSCs)is considered to be the internal factor of tumor occurrence and development,as well as the important reason of tumor recurrence,metastasis and resistance to radiotherapy and chemotherapy.CD44 is a transmembrane single-chain glycoprotein that can bind to a variety of ligands and has been proved to be a biomarker of CSCs in many kinds of malignant tumors.After selective splicing,there are many subtypes of CD44,such as standard type(CD44s)and variant type(CD44v).CD44 and its subtypes can be used in the diagnosis,treatment and prognosis of tumors,and their role has also been widely studied in the occurrence and development of digestive system malignant tumors.This review highlights the recent advances in the CD44-targeted therapies and the relationship between CD44 and digestive system tumors,in order to provide reference for clinical diagnosis and treatment of digestive system diseases.